UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.861

Sortiert nach

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1475-1495

2021

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

The New England journal of medicine, 2019-07, Vol.381 (4), p.307-316

2019

Link zum Volltext

Verfügbarkeit prüfen

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Annals of oncology, 2020-11, Vol.31 (11), p.1526-1535

2020

Link zum Volltext

Verfügbarkeit prüfen

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1148-1156

2021

Link zum Volltext

Verfügbarkeit prüfen

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Annals of oncology, 2022-03, Vol.33 (3), p.321-329

2022

Link zum Volltext

Verfügbarkeit prüfen

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Annals of oncology, 2018-09, Vol.29 (9), p.1939-1947

2018

Link zum Volltext

Verfügbarkeit prüfen

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

Breast (Edinburgh), 2016-08, Vol.28, p.191-198

2016

Link zum Volltext

Verfügbarkeit prüfen

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

Annals of oncology, 2022-03, Vol.33 (3), p.234-238

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract ES1-3: The ideal partner to HER2 directed therapies

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.ES1-3-ES1-3

Hurvitz, S

2022

Link zum Volltext

Verfügbarkeit prüfen

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

European journal of cancer (1990), 2018-11, Vol.104, p.160-168

2018

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]

Annals of oncology, 2023-07, Vol.34 (7), p.630-630

2023

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”: [Annals of Oncology 32 (2021) 950-953]

Annals of oncology, 2022-03, Vol.33 (3), p.356-356

2022

Link zum Volltext

Verfügbarkeit prüfen

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria

Annals of oncology, 2021-08, Vol.32 (8), p.950-953

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

Annals of oncology, 2018-10, Vol.29, p.viii121-viii121

2018

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

Annals of oncology, 2018-10, Vol.29, p.viii91-viii91

2018

Link zum Volltext

Verfügbarkeit prüfen

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

Annals of oncology, 2018-10, Vol.29, p.viii96-viii97

2018

Link zum Volltext

Verfügbarkeit prüfen

Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis

Annals of oncology, 2018-10, Vol.29, p.viii106-viii107

2018

Link zum Volltext

Verfügbarkeit prüfen

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Annals of oncology, 2018-10, Vol.29, p.viii96-viii96

2018

Link zum Volltext

Verfügbarkeit prüfen

Statistical controversies in clinical research: statistical significance—too much of a good thing

Annals of oncology, 2016-05, Vol.27 (5), p.760-762

2016

Link zum Volltext

Verfügbarkeit prüfen

Multidisciplinary Breast Clinic: Impact on Pretreatment Evaluation, Timeliness, and Guideline Concordant Care

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E11-E11

2016

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

ESMO open, 2024-05, Vol.9 (5), p.102924-102924, Article 102924

2024

Link zum Volltext

Verfügbarkeit prüfen

Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2- breast cancer

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi25

2017

Link zum Volltext

Verfügbarkeit prüfen

Some congenital diseases may just show up later

Journal of clinical sleep medicine, 2020-11, Vol.16 (11), p.1835-1836

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.861

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.499)
Mit Volltextzugriff
(1.631)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(634)
Life Sciences & Biomedicine
(586)
Humans
(467)
Female
(349)
Male
(247)
Adult
(169)
Oncology
(165)
Middle Aged
(136)
Biological And Medical Sciences
(130)
Medical Sciences
(121)
Animals
(119)
Breast Cancer
(105)
Aged
(104)
Adolescent
(82)
Child
(78)
Breast Neoplasms - Drug Therapy
(77)
Pediatrics
(77)
Cerebral Palsy
(67)
Trois Royaumes, Chin, Dynasties Du Nord Et Du Sud
(66)
General & Internal Medicine
(61)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Abstract ES1-3: The ideal partner to HER2 directed therapies

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]

Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”: [Annals of Oncology 32 (2021) 950-953]

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria

A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Statistical controversies in clinical research: statistical significance—too much of a good thing

Multidisciplinary Breast Clinic: Impact on Pretreatment Evaluation, Timeliness, and Guideline Concordant Care

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2- breast cancer

Some congenital diseases may just show up later

Suchergebnisse filtern